Special Issue

Papers from the BACR Conference-Response and Resistance in Cancer Therapy

Guest Editor(s):

Dr. Tim Fenton
School of Biosciences,
University of Kent, Canterbury
CT2 7NJ, UK.
E-Mail: T.Fenton@kent.ac.uk

Prof. Michelle Garrett
School of Biosciences,
University of Kent, Canterbury
CT2 7NJ, UK.
E-Mail: M.D.Garrett@kent.ac.uk

Prof. Martin Michaelis
School of Biosciences,
University of Kent, Canterbury
CT2 7NJ, UK.
E-Mail: M.Michaelis@kent.ac.uk

Dr. Mark Wass
School of Biosciences,
University of Kent, Canterbury
CT2 7NJ, UK.
E-Mail: M.N.Wass@kent.ac.uk

Special Issue Introduction

This Special Issue will consist of A Selection of Papers from BACR Conference---Response and Resistance in Cancer Therapy (https://www.bacr.org.uk/events/166), held in University of Kent, Canterbury, UK, on 10th–12th September 2018. Despite substantial improvements in recent decades, the prognosis for those cancer patients who suffer from metastatic disease and depend on systemic drug therapy remains poor. Both intrinsic resistance and the formation of acquired drug resistance substantially affects the efficacy of cancer drugs. The advancement of precision medicine approaches holds promise for both the effective guidance of therapies to patients that will respond and the ability to monitor this tumour response. This will require the successful interpretation of 'omics' data and a close collaboration between pre-clinical researchers, clinicians, and computational biologists in both academia and industry to develop these strategies. This conference will bring together and showcase cancer researchers from these areas, who will present and discuss the latest advances in understanding the mechanisms of drug resistance in cancer, the identification of biomarkers of drug sensitivity/resistance and how they can be linked to precision medicine approaches. This Special Issue will cover new and novel areas of research pertaining to Cancer Drug Resistance presented at this conference and therefore will represent state-of-the-art and up-to-date coverage of progress.

Benefits

Rigorous peer review: one manuscript must be reviewed by at least two experts in this field. We will ensure high standards for the review process and subsequent publication by a team of efficient and professional reviewers and scientific editors.

No publication fee: there would be absolutely no charge for publication. Rapid publication: we will ensure that accepted papers will be published in a short processing time (the average processing time: 61 days) with a high quality.

Open access: As an author you will retain the copyright to your work. By licensing your work under the Creative Commons Attribution License, articles can be re-used and re-distributed without restriction, as long as the original work is correctly cited.

Wide promotion: Published articles will be promoted at academic conferences, through social networks for scientists and relevant indexing services.